8-K: Zimmer Biomet Recasts 2023 Financials Due to Segment Profit Revisions

Zimmer Biomet has filed an 8-K to recast certain financial information from its 2023 annual report due to revisions in how segment operating profits are measured.

Summary

• Zimmer Biomet has refiled certain financial information from its 2023 annual report on Form 10-K due to changes in how segment operating profits are measured.
• The revisions involve reclassifying certain costs, primarily research and development and marketing, from the Americas operating segment to Corporate items.
• Support function costs from operating segments are also now included in Corporate items, which is not considered a reportable segment.
• The company's net sales increased by 6.5 percent in 2023 compared to 2022, but were tempered by a negative 1.0 percent effect from changes in foreign currency exchange rates.
• Net earnings from continuing operations were $1,024.0 million in 2023, compared to $290.2 million in 2022, driven by higher net sales, favorable tax settlements, and lower operating expenses.
• Operating expenses declined primarily due to lower litigation-related, restructuring-related, and quality remediation-related charges.
• The company expects mid-single-digit revenue growth in 2024, with a negative 0.5 percent impact from foreign currency exchange rates.
• Operating profit is expected to increase in 2024 due to higher net sales and savings from restructuring plans, partially offset by higher intangible asset amortization and increased restructuring costs.
• The company's effective tax rate was 4.0 percent in 2023, primarily driven by unrecognized tax benefits determined to be effectively settled during the year.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the document highlights a necessary financial recast, it also shows strong sales growth and improved profitability. The company's forward-looking statements are also positive, indicating continued growth and efficiency improvements. However, there are some concerns about foreign currency exchange rate impacts and increased costs.

Positives

• Net sales increased by 6.5 percent in 2023, indicating strong demand for the company's products.
• Net earnings from continuing operations significantly increased to $1,024.0 million in 2023, demonstrating improved profitability.
• Operating expenses decreased due to lower litigation, restructuring, and quality remediation charges, indicating improved cost management.
• The company expects mid-single-digit revenue growth in 2024, suggesting continued positive momentum.
• Operating profit is expected to increase in 2024, indicating improved operational efficiency.

Negatives

• Changes in foreign currency exchange rates negatively impacted net sales by 1.0 percent in 2023.
• The company expects a negative 0.5 percent impact from foreign currency exchange rates on net sales in 2024.
• Operating profit increases in 2024 will be partially offset by higher intangible asset amortization and increased restructuring costs.
• Net interest expense is expected to increase slightly due to higher interest rates.
• The provision for income taxes is expected to increase in 2024 due to the European Union adoption of Pillar Two and the non-reoccurrence of favorable tax settlements.

Risks

• The company is exposed to foreign currency exchange rate fluctuations, which can negatively impact net sales and profitability.
• Higher interest rates may increase net interest expense, affecting profitability.
• Increased restructuring costs may offset some of the benefits from restructuring plans.
• Changes in tax laws, including the European Union adoption of Pillar Two, may increase the provision for income taxes.
• The company is subject to various litigation matters, which could result in significant liabilities.

Future Outlook

The company expects mid-single-digit revenue growth in 2024, with a negative 0.5 percent impact from foreign currency exchange rates. Operating profit is expected to increase due to higher net sales and savings from restructuring plans, partially offset by higher intangible asset amortization and increased restructuring costs. Net interest expense is expected to increase slightly due to higher interest rates. The provision for income taxes is expected to increase due to the European Union adoption of Pillar Two and the non-reoccurrence of favorable tax settlements.

Management Comments

• Management expects year-over-year revenue growth of mid-single digits in 2024.
• Management estimates operating profit will increase in 2024 when compared to 2023 due to higher net sales, leverage from fixed operating expenses and savings from our restructuring plans.

Industry Context

This announcement reflects a common practice of companies adjusting their financial reporting to reflect changes in internal management structures and accounting practices. The recasting of segment operating profit measures is not uncommon and is often done to provide a more accurate view of business performance to investors and stakeholders. The company's focus on cost reduction and restructuring is also in line with broader industry trends of companies seeking to improve efficiency and profitability.

Comparison to Industry Standards

• The company's 6.5% net sales growth in 2023 is a positive sign, indicating a recovery from previous disruptions and is comparable to other large medical device companies.
• The increase in net earnings from continuing operations to $1,024.0 million in 2023 is a significant improvement and is a positive indicator of the company's financial health.
• The company's restructuring efforts and cost reduction initiatives are similar to those undertaken by other companies in the medical device industry to improve profitability.
• The company's focus on new product introductions and commercial execution is consistent with industry best practices for driving growth.
• The company's exposure to foreign currency exchange rate fluctuations is a common risk for multinational companies in the medical device industry.

Legal Proceedings

• The company is involved in various legal proceedings, including product liability, intellectual property, stockholder matters, tax disputes, commercial disputes, employment matters, whistleblower and qui tam claims and investigations, governmental proceedings and investigations, and other legal matters.
• The company is a defendant in a number of product liability lawsuits relating to its M/L Taper and M/L Taper with Kinectiv Technology hip stems, and Versys Femoral Head implants.
• The company is a defendant in a number of product liability lawsuits relating to metal-on-metal hip implants, most of which involve the M2a-Magnum hip system.
• The company is in the process of addressing various FDA Form 483 inspectional observations at certain of its manufacturing facilities.

Stakeholder Impact

• Shareholders will be impacted by the recast of financial information and the company's future performance.
• Employees may be impacted by the ongoing restructuring plans.
• Customers will benefit from the company's new product introductions and improved supply chain.
• Suppliers may be impacted by the company's cost reduction initiatives.
• Creditors will be impacted by the company's debt obligations and financial performance.

Next Steps

• The company will continue to implement its 2023 Restructuring Plan.
• The company will continue to monitor the fair value of its reporting units.
• The company will continue to address various FDA Form 483 inspectional observations.
• The company will continue to defend its tax positions with the IRS.

Key Dates

Keywords

financial recast, segment operating profit, revenue growth, restructuring, operating expenses, net earnings, foreign currency, intangible asset amortization, tax settlements, medical devices